CVT Hopes MERLIN Is Magic: Can Outcomes Trial Reverse Ranexa’s Fortune?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Large outcomes studies "will be the wave of the future for many products, not just cardiovascular products," CV Therapeutics CEO Louis Lange predicted during a Feb. 8 earnings call.